Treatment of Gram-negative bacillary meningitis with intrathecal gentamicin.
In order to evaluate the effect of intrathecal gentamicin on gram-negative bacillary meningitis, twenty-eight patients were treated with intralumbar or intraventricular gentamicin in combination with systemic gentamicin and with other antibiotics. Sterile cerebrospinal fluid was achieved in 21/22 (95%) episodes of documented gram-negative bacillary meningitis in patients who received more than one day of therapy. Seventy-seven percent of these patients survived their infection. The mean cerebrospinal fluid gentamicin level measured 24 hours after intrathecal administration was 5.9 ug/ml following intralumbar administration and 11.1 ug/ml following intraventricular administration. Toxic side effects due to intrathecal administration of gentamicin were not noted. These findings suggest that both intralumbar and intraventricular administration of gentamicin are safe and efficacious in the treatment of gram-negative bacillary meningitis.
D000328:Adult; D001812:Blood-Brain Barrier; D002555:Cerebrospinal Fluid / Q000382:microbiology; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage / Q000134:cerebrospinal fluid / Q000627:therapeutic use*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007276:Injections, Intraventricular; D007278:Injections, Spinal; D008297:Male; D008581:Meningitis / Q000188:drug therapy* / Q000382:microbiology; D008875:Middle Aged
D005839:Gentamicins